-
-
Pharma & Human Health -
Pharma & Human Health -
Finance -
Editor's Choice
Editor’s Choice
Editor's Choice
Food for Health: A new direction for American Agriculture
Over the past two years during this global pandemic, it has become clear that regrettably, those of us who are the most vulnerable to severe disease from SARS-CoV-2 are the ones with underlying chronic diseases […]
Editor's Choice
CRISPRing the microbiome is just around the corner
To date, CRISPR enzymes have been used to edit the genomes of one type of cell at a time: They cut, delete or add genes to a specific kind of cell within a tissue or […]
Biotech Showcase
Bringing the Transformative Power of Synthetic Biology to Medicine
This presentation was part of the Biotech Showcase at the Pharmabiotic Research Institute’s Annual Event, Pharmabiotics Conference & Partnering. The PRI is Europe’s leading microbiome regulatory science expertise center and was founded in 2010 […]
In Case you Missed it:
Finance
EverImmune engages Biose Industrie to manufacture its leading oncology-related Live Biotherapeutic
Microbiome-focused oncology drug company everImmune, a spin-out from France’s top cancer research center, has signed an agreement with contract development and manufacturing organization (CDMO) Biose Industrie to manufacture the drug substance and finished drug product […]
Editor's Choice
CRISPRing the microbiome is just around the corner
To date, CRISPR enzymes have been used to edit the genomes of one type of cell at a time: They cut, delete or add genes to a specific kind of cell within a tissue or […]
Biotech Showcase
Bringing the Transformative Power of Synthetic Biology to Medicine
This presentation was part of the Biotech Showcase at the Pharmabiotic Research Institute’s Annual Event, Pharmabiotics Conference & Partnering. The PRI is Europe’s leading microbiome regulatory science expertise center and was founded in 2010 […]
Pharma & Human Health
Axial Therapeutics Doses First Subjects in Global Phase 2b Clinical Trial for Irritability Associated with ASD
Axial Therapeutics, a clinical-stage biopharmaceutical company dedicated to improving the lives of people with neurological conditions, today announced that the first subjects have successfully received their first dose in the company’s global Phase 2b clinical […]
Editor's Choice
Eligo Bioscience Announces Successful Outcome in US Patent Interference against SNIPR Biome
Eligo Bioscience today announced that the US Patent and Trademark Office (USPTO) has issued on Nov 19, 2021, a decision and a judgement acknowledging priority to the invention of precision bacterial killing using CRISPR to […]
